Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Jan 22;321(3):306-307.
doi: 10.1001/jama.2018.18085.

Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

Fabrice Denis  1 , Ethan Basch  2 , Anne-Lise Septans  3 , Jaafar Bennouna  4 , Thierry Urban  5 , Amylou C Dueck  6 , Christophe Letellier  7
Affiliations
Randomized Controlled Trial

Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

Fabrice Denis et al. JAMA. .

Abstract

This study reports 2-year survival outcomes among patients with advanced nonprogressive stage IIA to IV lung cancer randomized to symptom monitoring during chemotherapy via web-based patient-reported outcomes vs standard scheduled imaging after treatment to detect symptomatic recurrence.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Denis reported receiving personal fees from AstraZeneca, Ipsen, SIVAN Innovation, Pfizer, Chugai, and Roche. Dr Basch reported receiving research funding from the National Cancer Institute and Patient-Centered Outcomes Research Institute and personal fees (ie, payment for serving on the scientific advisory board) from the Centers for Medicare & Medicaid Services, SIVAN Innovation, and Noona. Dr Bennouna reported receiving personal fees from Lilly and Merck Sharp & Dohme. Dr Urban reported receiving personal fees from AstraZeneca and Novartis. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Assignment, Follow-up, and Analysis of the Study Patients
At 9 months when recruitment was halted, 10 patients in the intervention group and 27 patients in the control group had died. Of the 34 living patients in the control group, 10 had not relapsed and crossed over to the intervention.
Figure 2.
Figure 2.. Kaplan-Meier Curves for the Overall Survival (OS) Analysis
A total of 121 patients were included in the intention-to-treat survival analysis. Ten of 34 living patients in the control group were eligible to cross over following the interim analysis. HR indicates hazard ratio.
See this image and copyright information in PMC

References

    1. Basch E, Deal AM, Dueck AC, et al. . Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318(2):197-198. doi:10.1001/jama.2017.7156 - DOI - PMC - PubMed
    1. Denis F, Lethrosne C, Pourel N, et al. . Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. J Natl Cancer Inst. 2017;109(9). doi:10.1093/jnci/djx029 - DOI - PubMed
    1. Denis F, Yossi S, Septans AL, et al. . Improving survival in patient treated for a lung cancer using self-evaluated symptoms reported through a web application. Am J Clin Oncol. 2017;40(5):464-469. doi:10.1097/COC.0000000000000189 - DOI - PubMed
    1. Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory Methods. 1991;20:2609-2631. doi:10.1080/03610929108830654 - DOI

Publication types